Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 11/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.82 |
| ▸ | MYLK | Q15746 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CRY1 | Q16526 | 4/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.37 |
| ▸ | PER2 | O15055 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3623830 | 0.90 | KCNA5 (1.00) | KCNA5KCNH2DPP4MAPK8KDM4E | |
| SCHEMBL3613934 | 0.90 | KCNA5 (0.81) | KCNA5KCNH2MYLKDPP4MAPK8 | |
| SCHEMBL3621068 | 0.83 | KCNA5 (1.00) | KCNA5KCNH2DPP4MAPK8KDM4E | |
| SCHEMBL13256571 | 0.82 | KCNA5 (0.73) | KCNA5KCNH2DPP4MAPK8 | |
| SCHEMBL3625507 | 0.82 | KCNA5 (0.73) | KCNA5KCNH2DPP4MAPK8 | |
| SCHEMBL13256570 | 0.82 | KCNA5 (0.73) | KCNA5KCNH2DPP4MAPK8 | |
| SCHEMBL1384172 | 0.82 | KCNA5 (0.78) | KCNA5KCNH2DPP4MAPK8KDM4E | |
| SCHEMBL3624319 | 0.82 | KCNA5 (0.85) | KCNA5KCNH2DPP4MAPK8 | |
| SCHEMBL13256552 | 0.82 | KCNA5 (0.84) | KCNA5KCNH2DPP4MAPK8KDM4E | |
| SCHEMBL3623960 | 0.81 | KCNA5 (0.89) | KCNA5KCNH2DPP4MAPK8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4824563-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| US-7763614-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-07-27 | — | — | US | claimed |
| EP-1667981-A4 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | claimed |
| US-20070054892-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-08 | — | — | US | claimed |
| EP-1667981-A1 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005030729-A1 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |
| US-7763614-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070054892-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054892-A1 | Isoquinoline potassium channel inhibitors | KCNQ1, KCNQ2, KCNQ5 | KCNA5 14/4885KCNH2 5/4885MYLK 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.